Development of a Novel Anti-HIV Oligonucleotide

Award Information
Agency:
Department of Health and Human Services
Amount:
$98,800.00
Program:
SBIR
Contract:
1 R43 AI38788-01,
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
N/A
Award Year:
1995
Phase:
Phase I
Agency Tracking Number:
29153
Solicitation Topic Code:
N/A
Small Business Information
Triplex Pharmaceutical
9391 Grogans Mill Road, The Woodlands, TX, 77380
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 Thomas Wallace
 () -
Business Contact
Phone: () -
Research Institution
N/A
Abstract
AIDS is a fatal disorder of the immune system caused by the HIV and is a widespread epidemic. The lobjective of this work is to treat human AIDS patients with a novel oligonucleotide (T30177) that haanti-HIV activity. We will perform preclinical animal pharmacology studies, including pharmacokinetiand toxicity studies in mice. One of these aims includes investigating a novel in vivo route of admioligonucleotides. Although there are a number of drugs that are currently available for the treatmenhave limited effectiveness and only delay the progression to death of AIDS patients. There is a greadevelopment of more effective and novel drugs for the treatment of AIDS. T30177 may provide significpresently available HIV drugs because it has a novel mechanism of action, it is active against AZT-rbeen shown in pilot animal studies to have a long half-life, good stability, and low toxicity.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government